Condition: Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy · Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This study was designed to compare the efficacy and safety of SHR2554 with Chidamide in patients with relapsed/refractory PTCL.
This description comes directly from the study's public registry record.
Min Li · 0518-82342973 · Min.li.ml150@hengrui.com
Always discuss trial participation with your own doctor first.
| Peking University Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06122389